DACH1 a key protein for tumor suppression in ER+ breast cancer

Jul 15, 2009

Researchers from the Kimmel Cancer Center at Jefferson have identified a protein relationship that may be an ideal treatment target for ER+ breast cancer. The study was reported in the July 15 issue of Cancer Research.

DACH1, a cell fate determination factor , prevents cancer by repressing the function of receptorsin breast cancer, the researchers found. However, they also found that as the presence of DACH1 decreases in breast cancer, the presence of estrogen receptors increases, and vice versa.

Approximately 70% of breast cancers are ER+. Treatment for ER+ breast cancer usually consists of hormone therapy, which includes lowering the natural estrogen levels in the body or using synthetic drugs like tamoxifen, which compete with natural estrogen. However, this treatment only works for a few years.

"Eventually, will circumvent the estrogen-dependent growth and find a different pathway through which they will proliferate," said Vladimir Popov, a doctoral student in Biochemistry and Molecular Biology at Jefferson College of Graduate Studies of Thomas Jefferson University and the study's first author. "Our lab has shown that there is a correlation between DACH1 and estrogen receptors. DACH1 is a naturally occurring repressor of function in normal breast tissue, which makes it a promising therapeutic target for patients with ER+ breast cancer."

DACH1 is expressed in normal breast tissue. As breast cancer develops and becomes more invasive, the expression of DACH1 decreases. In a previous study of more than 2,000 breast cancer patients, Jefferson researchers found that a lack of DACH1 expression was associated with a poor prognosis. Patients who did express DACH1 lived an average of 40 months longer.

"Many more studies need to be done, but there is strong evidence that DACH1 is a promising marker of survival and therapeutic target in patients with ," said the study's senior researcher Richard Pestell, M.D., Ph.D, who is director of the Kimmel Cancer Center and chair of the Cancer Biology department at Jefferson.

Source: Thomas Jefferson University (news : web)

Explore further: No increased risk of second cancers with radiotx in pelvic CA

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Scientists zero in on how lung cancer spreads

Dec 24, 2014

Cancer Research UK scientists have taken microscopic images revealing that the protein ties tethering cells together are severed in lung cancer cells - meaning they can break loose and spread, according to ...

Scientists identify rare cancer's genetic pathways

Dec 24, 2014

An international research team, including four Simon Fraser University scientists, has identified the "mutational landscape" of intrahepatic cholangiocarcinoma (ICC), a rare, highly fatal form of liver cancer that disproportionately ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.